Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CCNH | P51946 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953146 | 0.80 | — | — | |
| SCHEMBL1375993 | 0.75 | PAK1 (0.51) | ALDH1A1PAK1KDM4ERXFP1CDK2 | |
| SCHEMBL2951841 | 0.72 | PAK1 (0.55) | ALDH1A1PAK1KDM4ERXFP1CDK2 | |
| SCHEMBL10869151 | 0.71 | PAK1 (0.57) | ALDH1A1PAK1KDM4ERXFP1CDK2 | |
| Hydrochloric Acid SCHEMBL6821631 | 0.71 | PAK1 (0.54) | ALDH1A1PAK1KDM4ERXFP1CDK2 | |
| SCHEMBL2953148 | 0.68 | METAP2 (0.34) | — | |
| SCHEMBL9854792 | 0.67 | ALDH1A1 (0.46) | ALDH1A1PAK1KDM4ERXFP1CDK2 | |
| SCHEMBL2388908 | 0.67 | PAK1 (0.46) | ALDH1A1PAK1KDM4ERXFP1CDK2 | |
| SCHEMBL31380702 | 0.66 | ALDH1A1 (0.45) | ALDH1A1PAK1KDM4ERXFP1CDK2 | |
| SCHEMBL5872330 | 0.66 | PAK1 (0.45) | ALDH1A1PAK1KDM4ERXFP1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | ALDH1A1 238/4885PAK1 663/4885KDM4E 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.